Literature DB >> 17873307

Clinical stage-depending decrease of NK cell activity in multiple myeloma patients.

Vladimir Jurisic1, Tatjana Srdic, Gordana Konjevic, Olivera Markovic, Milica Colovic.   

Abstract

Natural killer cells, as an important subpopulation of cells of the innate immune system have an essential role in defense of the rise and spread of malignancy. These cells have a CD3-CD16 + CD56+ phenotype and they are functionally defined by their ability to lyses tumor cells. We here show that decrease of NK cell activity was significantly associated with advanced clinical stage, increased lactate dehydrogenase (LDH), percentage infiltration of bone marrow with plasma cells, and beta-2 microglobulin. The patients with higher NK cell activity at presentation after receiving VAD protocol have better cumulative survival in comparison with those with low NK cell activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17873307     DOI: 10.1007/s12032-007-0007-y

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  25 in total

1.  IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC.

Authors:  Gordana Konjević; Viktor Jović; Vladimir Jurisić; Sinisa Radulović; Svetislav Jelić; Ivan Spuzić
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

Review 2.  Biology and clinical relevance of human natural killer cells.

Authors:  M J Robertson; J Ritz
Journal:  Blood       Date:  1990-12-15       Impact factor: 22.113

3.  Estimation of cell membrane alteration after drug treatment by LDH release.

Authors:  Vladimir Jurisic
Journal:  Blood       Date:  2003-04-01       Impact factor: 22.113

Review 4.  Natural killer cells: immunobiology and clinical prospects.

Authors:  E Lotzová
Journal:  Cancer Invest       Date:  1991       Impact factor: 2.176

5.  Perforin is a major contributor to NK cell control of tumor metastasis.

Authors:  M J Smyth; K Y Thia; E Cretney; J M Kelly; M B Snook; C A Forbes; A A Scalzo
Journal:  J Immunol       Date:  1999-06-01       Impact factor: 5.422

Review 6.  The role of natural killer cells in immune surveillance of cancer.

Authors:  T L Whiteside; R B Herberman
Journal:  Curr Opin Immunol       Date:  1995-10       Impact factor: 7.486

7.  Natural killer cell suppression of IgM production.

Authors:  S Che; D P Huston
Journal:  Nat Immun       Date:  1994 Sep-Oct

8.  The difference in NK-cell activity between patients with non-Hodgkin's lymphomas and Hodgkin's disease.

Authors:  G Konjević; V Jurisić; B Banićevic; I Spuzić
Journal:  Br J Haematol       Date:  1999-01       Impact factor: 6.998

Review 9.  NK cells: innate immunity against hematological malignancies?

Authors:  Régis T Costello; Cyril Fauriat; Simona Sivori; Emanuela Marcenaro; Daniel Olive
Journal:  Trends Immunol       Date:  2004-06       Impact factor: 16.687

10.  TNF-alpha induces changes in LDH isotype profile following triggering of apoptosis in PBL of non-Hodgkin's lymphomas.

Authors:  V Jurisic; V Bumbasirevic; G Konjevic; B Djuricic; I Spuzic
Journal:  Ann Hematol       Date:  2003-10-28       Impact factor: 3.673

View more
  44 in total

Review 1.  Multiple solitary plasmacytoma with multifocal bone involvement. First clinical case report in a uraemic patient.

Authors:  Pietro Dattolo; Marco Allinovi; Stefano Michelassi; Francesco Pizzarelli
Journal:  BMJ Case Rep       Date:  2013-05-23

Review 2.  Investigation of NK cell function and their modulation in different malignancies.

Authors:  Gordana Konjevic; Vladimir Jurisic; Viktor Jovic; Ana Vuletic; Katarina Mirjacic Martinovic; Sandra Radenkovic; Ivan Spuzic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

3.  Natural killer cell recognition of in vivo drug-induced senescent multiple myeloma cells.

Authors:  Fabrizio Antonangeli; Alessandra Soriani; Biancamaria Ricci; Andrea Ponzetta; Giorgia Benigni; Stefania Morrone; Giovanni Bernardini; Angela Santoni
Journal:  Oncoimmunology       Date:  2016-08-05       Impact factor: 8.110

Review 4.  Novel Immunotherapies for Multiple Myeloma.

Authors:  Mattia D'Agostino; Mario Boccadoro; Eric L Smith
Journal:  Curr Hematol Malig Rep       Date:  2017-08       Impact factor: 3.952

5.  Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication.

Authors:  A Arteche-López; A Kreutzman; A Alegre; P Sanz Martín; B Aguado; M González-Pardo; M Espiño; L M Villar; D García Belmonte; R de la Cámara; C Muñoz-Calleja
Journal:  Bone Marrow Transplant       Date:  2017-04-03       Impact factor: 5.483

Review 6.  Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.

Authors:  G Shay; L Hazlehurst; C C Lynch
Journal:  J Mol Med (Berl)       Date:  2015-10-01       Impact factor: 4.599

Review 7.  Immune checkpoint blockade for hematologic malignancies: a review.

Authors:  Matthew J Pianko; Yuzhou Liu; Srishti Bagchi; Alexander M Lesokhin
Journal:  Stem Cell Investig       Date:  2017-04-19

8.  Ophthalmic manifestations of herpes zoster virus in patients with multiple myeloma following bone marrow transplantation.

Authors:  Alhossain A Khalafallah; Miriam Woodgate; Kurien Koshy; Andrew Patrick
Journal:  BMJ Case Rep       Date:  2013-02-20

9.  SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide.

Authors:  H Jiang; C Acharya; G An; M Zhong; X Feng; L Wang; N Dasilva; Z Song; G Yang; F Adrian; L Qiu; P Richardson; N C Munshi; Y-T Tai; K C Anderson
Journal:  Leukemia       Date:  2015-09-04       Impact factor: 11.528

10.  Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma.

Authors:  Yi Hu; Huimin Liu; Chuanfeng Fang; Chen Li; Fjorela Xhyliu; Hayley Dysert; Juraj Bodo; Gabriel Habermehl; Benjamin E Russell; Wenjun Li; Marcia Chappell; Xiaofeng Jiang; Sarah L Ondrejka; Eric D Hsi; Jaroslaw P Maciejewski; Qing Yi; Kenneth C Anderson; Nikhil C Munshi; Geyou Ao; Jason N Valent; Jianhong Lin; Jianjun Zhao
Journal:  Cancer Res       Date:  2020-03-19       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.